Harvard Bioscience (HBIO) Given Daily News Sentiment Rating of 0.08
Media stories about Harvard Bioscience (NASDAQ:HBIO) have trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Harvard Bioscience earned a news impact score of 0.08 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.2847316742766 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Harvard Bioscience (NASDAQ HBIO) opened at $3.30 on Wednesday. Harvard Bioscience has a 1 year low of $2.25 and a 1 year high of $3.90. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40. The firm has a market cap of $114.23, a PE ratio of 109.17 and a beta of 1.00.
Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03. Harvard Bioscience had a negative net margin of 3.16% and a positive return on equity of 1.11%. The firm had revenue of $25.05 million during the quarter, compared to the consensus estimate of $24.60 million. analysts forecast that Harvard Bioscience will post 0.05 earnings per share for the current year.
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.